Haloperidol blocks the dopamine D2 receptor, so Pramipexole cannot act there — the effect of Pramipexole is reduced or lost.
Pramipexole is an agonist at the dopamine D2 receptor: it binds and switches the receptor on. Haloperidol is an antagonist at the same site and switches nothing on. With both present they compete for the same pocket, and whichever is there in greater effective concentration decides what the receptor does.
Given together they work against whatever each was started for. If both are genuinely needed, expect less of Pramipexole’s effect than its dose would suggest.
This is a pharmacodynamic interaction. Neither drug changes the other’s concentration, so a level, an AUC estimate or a genotype looks entirely normal while the clinical effect is blunted.
The direction can be the useful one. The same opposition is what makes a reversal agent, an antidote or a planned antagonist work.



The ring marks the peg each drug wears for this receptor — the same cross-illumination Interact! draws when the two are put side by side.

